Clinical trials: Pancreas Tumor
Pancreatic Cancer
Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas
This study is performed to confirm whether resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy could improve survival and relieve pain of pancreatic cancer patients.
- Trial name
- NCT02514928
- Testing
- resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy, standard pancreatoduodenectomy
- Where
- China
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable…
- Trial name
- PANCARDINAL-2 (NCT06831136)
- Testing
- Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastrointestinal Cancer, Cancer of Unknown Primary Site
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
Capecitabine is a chemotherapy drug used to treat many types of cancer including bowel and stomach cancer. Unfortunately a side effect of this drug is that it causes heart problems including heart attacks.
- Conditions
- Gastrointestinal Cancer, Cancer of Unknown Primary Site, Pancreatic Cancer, Bile Duct Neoplasms
- Trial name
- TOFFEE (NCT01845337)
- Testing
- Teysuno, Capecitabine
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- University of Edinburgh
Pancreatic Cancer
Oncologist-Initiated Cancer Genetic Testing for Pancreatic Cancer Patients
Pancreatic cancer (PC) has a dismal prognosis. Approximately 10% of PC patients carry a germline pathogenic variant in a cancer susceptibility gene, whose identification can lead to better treatments for the patient and…
- Trial name
- NCT04316507
- Testing
- Genetic Counselling and Testing
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Pancreatic Cancer, Unresectable Biliary-pancreatic Malignancies
Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
The purpose of this study is to compare the effects good and/or bad of combining radiofrequency ablation with placement of a second stent, versus a second stent alone.
- Trial name
- NCT02340728
- Testing
- ERCP with SEMS plus radiofrequency ablation, ERCP with SEMS alone (standard of care)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
This phase I trial is studying the side effects and best dose of dovitinib lactate when given together with gemcitabine hydrochloride and capecitabine in treating patients with advanced or metastatic solid tumors or advanced…
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01497392
- Testing
- dovitinib lactate, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Adenocarcinoma, Cholangiocarcinoma
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC).
- Conditions
- Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Adenocarcinoma
- Trial name
- NCT02638909
- Testing
- ceritinib
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Criterium, Inc.
Pancreatic Cancer
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab…
- Trial name
- NCT06782932
- Testing
- AGEN2373, Balstilimab, Cyclophosphamide
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Cholangiocarcinoma, Hepatocellular Carcinoma
In Vitro Models of Liver and Pancreatic Cancer
The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue.
- Conditions
- Cholangiocarcinoma, Hepatocellular Carcinoma, Pancreatic Neoplasm
- Trial name
- NCT02436564
- Testing
- Organoid in vitro culture
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Bile Omics for Diagnosing Indeterminate Biliary Strictures
The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to improve detection rates.
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
- Trial name
- NCT07007832
- Testing
- Endoscopic retrograde cholangiopancreatography
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neoplasm, Hepatic, Pancreatic Neoplasms
Impact of Microparticles on Postoperative Complications in Surgical Patients
Microparticles are cellular fragments which are released actively or passively under conditions of inflammation and stress. The impact of surgical operations on quantity and quality of microparticles remains unknown.
- Conditions
- Neoplasm, Hepatic, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00677781
- Where
- Switzerland
- Volunteers
- 108 people
- Sponsor
- University of Bern
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Cyst
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine/Metabolic/Inflammatory (EMI)…
- Trial name
- EMI-IPMN (NCT06706700)
- Where
- Italy
- Volunteers
- 586 people
- Sponsor
- IRCCS San Raffaele
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Metastatic Pancreatic Cancer
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
Inclusion 1. Subjects who are males or females ≥ 19 years of age 2. Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic…
- Trial name
- MP-PDAC-01 (NCT03666832)
- Testing
- TEW-7197
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Joon Oh Park
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Insulinoma
The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic…
- Trial name
- NCT04979611
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cholangiocarcinoma, Pancreatic Cancer
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
The purpose of this study is to assess safety and ability of the endoscopic bipolar radiofrequency ablation (RFA) probe (ENDOHPB) to produce an improvement in the management of cancer of the bile duct or the pancreatic duct.
- Trial name
- NCT01303159
- Testing
- Endoscopic bipolar radiofrequency probe (ENDOHPB)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.